Advertisement

Topics

FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

04:24 EDT 24 Sep 2018 | News-Medical.net

Epizyme, Inc., a clinical-stage company developing novel epigenetic therapies, today announced the U.S. Food and Drug Administration has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials.

Original Article: FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials

NEXT ARTICLE

More From BioPortfolio on "FDA lifts partial clinical hold that paused enrollment of new patients in tazemetosta clinical trials"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Epigenetics
The development and maintenance of an organism is orchestrated by a set of chemical reactions that switch parts of the genome off and on at strategic times and locations. Epigenetics is the study of these reactions and the factors that influence them. ...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...